Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study

Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study

<i>Background and Objectives</i>: Remdesivir (RDV) is the first antiviral agent approved in Japan for the treatment of coronavirus disease 2019 (COVID-19). The aim of our study was to assess the efficacy and safety of RDV treatment in mildly to moderately ill patients with COVID-19. <...

Full description

Bibliographic Details
Main Authors: Motoyasu Miyazaki, Ryoko Yanagida, Akio Nakashima, Koichi Matsuo, Norihiro Moriwaki, Masanobu Uchiyama, Yota Yamada, Hitomi Hirata, Hisako Kushima, Yoshiaki Kinoshita, Hiroshi Ishii, Osamu Imakyure
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Medicina
Subjects:
coronavirus
COVID-19
remdesivir
oxygen therapy
Online Access:https://www.mdpi.com/1648-9144/58/8/1007

Internet

https://www.mdpi.com/1648-9144/58/8/1007

Similar Items